|
1
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Slamon DJ, Godolphin W, Jones LA, Holt JA,
Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tan M, Yao J and Yu D: Overexpression of
the c-erbB-2 gene enhanced intrinsic metastasis potential in human
breast cancer cells without increasing their transformation
abilities. Cancer Res. 57:1199–1205. 1997.PubMed/NCBI
|
|
5
|
Yu D and Hung MC: Overexpression of ErbB2
in cancer and ErbB2-targeting strategies. Oncogene. 19:6115–6121.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Knuefermann C, Lu Y, Liu B, Jin W, Liang
K, Wu L, Schmidt M, Mills GB, Mendelsohn J and Fan Z:
HER2//PI-3K//Akt activation leads to a multidrug resistance in
human breast adenocarcinoma cells. Oncogene. 22:3205–3212. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hudis CA: Trastuzumab-mechanism of action
and use in clinical practice. N Engl J Med. 357:39–51. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Perez EA, Romond EH, Suman VJ, Jeong JH,
Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA and
Wolmark N: Four-year follow-up of trastuzumab plus adjuvant
chemotherapy for operable human epidermal growth factor receptor
2-positive breast cancer: Joint analysis of data from NCCTG N9831
and NSABP B-31. J Clin Oncol. 29:3366–3373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Singh JC, Jhaveri K and Esteva FJ:
HER2-positive advanced breast cancer: Optimizing patient outcomes
and opportunities for drug development. Br J Cancer. 111:1888–1898.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rimawi MF, Schiff R and Osborne CK:
Targeting HER2 for the treatment of breast cancer. Annu Rev Med.
66:111–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Swain SM, Baselga J, Kim SB, Ro J,
Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A,
Heeson S, et al: Pertuzumab, trastuzumab, and docetaxel in
HER2-positive metastatic breast cancer. N Engl J Med. 372:724–734.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mukohara T: Role of HER2-targeted agents
in adjuvant treatment for breast cancer. Chemother Res Pract.
2011:7303602011.PubMed/NCBI
|
|
13
|
deAzambuja E, Holmes AP, Piccart-Gebhart
M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I,
Smith I, et al: Lapatinib with trastuzumab for HER2-positive early
breast cancer (NeoALTTO): Survival outcomes of a randomised,
open-label, multicentre, phase 3 trial and their association with
pathological complete response. Lancet Oncol. 15:1137–1146. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hahn KA, Ogilvie G, Rusk T, Devauchelle P,
Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini
F, et al: Masitinib is safe and effective for the treatment of
canine mast cell tumors. J Vet Intern Med. 22:1301–1309. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
London CA, Malpas PB, Wood-Follis SL,
Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein
MK, Hintermeister JG, et al: Multi-center, placebo-controlled,
double-blind, randomized study of oral toceranib phosphate
(SU11654), a receptor tyrosine kinase inhibitor, for the treatment
of dogs with recurrent (either local or distant) mast cell tumor
following surgical excision. Clin Cancer Res. 15:3856–3865. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Paoloni M and Khanna C: Translation of new
cancer treatments from pet dogs to humans. Nat Rev Cancer.
8:147–156. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gamba CO, Dias EJ, Ribeiro LG, Campos LC,
Estrela-Lima A, Ferreira E and Cassali GD: Histopathological and
immunohistochemical assessment of invasive micropapillary mammary
carcinoma in dogs: A retrospective study. Vet J. 196:241–246. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ressel L, Puleio R, Loria GR, Vannozzi I,
Millanta F, Caracappa S and Poli A: HER-2 expression in canine
morphologically normal, hyperplastic and neoplastic mammary tissues
and its correlation with the clinical outcome. Res Vet Sci.
94:299–305. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Muhammadnejad A, Keyhani E, Mortazavi P,
Behjati F and Haghdoost IS: Overexpression of her-2/neu in
malignant mammary tumors; translation of clinicopathological
features from dog to human. Asian Pac J Cancer Prev. 13:6415–6421.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim JH, Im KS, Kim NH, Yhee JY, Nho WG and
Sur JH: Expression of HER-2 and nuclear localization of HER-3
protein in canine mammary tumors: Histopathological and
immunohistochemical study. Vet J. 189:318–322. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Singer J, Weichselbaumer M, Stockner T,
Mechtcheriakova D, Sobanov Y, Bajna E, Wrba F, Horvat R, Thalhammer
JG, Willmann M and Jensen-Jarolim E: Comparative oncology: ErbB-1
and ErbB-2 homologues in canine cancer are susceptible to cetuximab
and trastuzumab targeting. Mol Immunol. 50:200–209. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peña L, Gama A, Goldschmidt MH, Abadie J,
Benazzi C, Castagnaro M, Díez L, Gärtner F, Hellmén E, Kiupel M, et
al: Canine mammary tumors: A review and consensus of standard
guidelines on epithelial and myoepithelial phenotype markers, HER2,
and hormone receptor assessment using immunohistochemistry. Vet
Pathol. 51:127–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pichler WJ: Adverse side-effects to
biological agents. Allergy. 61:912–920. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Corominas M, Gastaminza G and Lobera T:
Hypersensitivity reactions to biological drugs. J Investig Allergol
Clin Immunol. 24:212–225. 2014.PubMed/NCBI
|
|
25
|
Baldo BA: Adverse events to monoclonal
antibodies used for cancer therapy: Focus on hypersensitivity
responses. Oncoimmunology. 2:e263332013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Singer J, Fazekas J, Wang W,
Weichselbaumer M, Matz M, Mader A, Steinfellner W, Meitz S,
Mechtcheriakova D, Sobanov Y, et al: Generation of a canine
anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer
patients. Mol Cancer Ther. 13:1777–1790. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rue SM, Eckelman BP, Efe JA, Bloink K,
Deveraux QL, Lowery D and Nasoff M: Identification of a candidate
therapeutic antibody for treatment of canine B-cell lymphoma. Vet
Immunol Immunopathol. 164:148–159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jensen-Jarolim E and Singer J: Cancer
vaccines inducing antibody production: More pros than cons. Expert
Rev Vaccines. 10:1281–1289. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Milani A, Sangiolo D, Montemurro F,
Aglietta M and Valabrega G: Active immunotherapy in HER2
overexpressing breast cancer: Current status and future
perspectives. Ann Oncol. 24:1740–1748. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anderson KS: Tumor vaccines for breast
cancer. Cancer Invest. 27:361–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sears AK, Perez SA, Clifton GT, Benavides
LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC,
Carmichael MG, et al: AE37: A novel T-cell-eliciting vaccine for
breast cancer. Expert Opin Biol Ther. 11:1543–1550. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
NCT01730118, . Ad/HER2/Neu dendritic cell
cancer vaccine testing. https://clinicaltrials.gov/Accessed. August
31–2015
|
|
33
|
Knittelfelder R, Riemer AB and
Jensen-Jarolim E: Mimotope vaccination-from allergy to cancer.
Expert Opin Biol Ther. 9:493–506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ashok BT, David L, Chen YG, Garikapaty VP,
Chander B, Kanduc D, Mittelman A and Tiwari RK: Peptide mimotopes
of oncoproteins as therapeutic agents in breast cancer. Int J Mol
Med. 11:465–471. 2003.PubMed/NCBI
|
|
35
|
Riemer AB, Kurz H, Klinger M, Scheiner O,
Zielinski CC and Jensen-Jarolim E: Vaccination with cetuximab
mimotopes and biological properties of induced anti-epidermal
growth factor receptor antibodies. J Natl Cancer Inst.
97:1663–1670. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Riemer AB, Kraml G, Scheiner O, Zielinski
CC and Jensen-Jarolim E: Matching of trastuzumab (Herceptin)
epitope mimics onto the surface of Her-2/neu-a new method of
epitope definition. Mol Immunol. 42:1121–1124. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Riemer AB, Klinger M, Wagner S, Bernhaus
A, Mazzucchelli L, Pehamberger H, Scheiner O, Zielinski CC and
Jensen-Jarolim E: Generation of Peptide mimics of the epitope
recognized by trastuzumab on the oncogenic protein Her-2/neu. J
Immunol. 173:394–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Manzano-Szalai K, Thell K, Willensdorfer
A, Weghofer M, Pfanzagl B, Singer J, Ritter M, Stremnitzer C,
Flaschberger I, Michaelis U and Jensen-Jarolim E: Adeno-associated
virus-like particles as new carriers for B-cell vaccines: Testing
immunogenicity and safety in BALB/c mice. Viral Immunol.
27:438–448. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Singer J, Manzano-Szalai K, Fazekas J,
Thell K, Bentley-Lukschal A, Stremnitzer C, Roth-Walter F, Weghofer
M, Ritter M, Tossi KP, et al: Proof of concept study with a HER-2
mimotope anti-cancer vaccine deduced from a novel AAV-mimotope
library platform. Oncoimmunology. e11714462016. View Article : Google Scholar
|
|
40
|
Valicsek E, Kószó R, Dobi Á, Uhercsák G,
Varga Z, Vass A, Jebelovszky É and Kahán Z: Cardiac surveillance
findings during adjuvant and palliative trastuzumab therapy in
patients with breast cancer. Anticancer Res. 35:4967–4973.
2015.PubMed/NCBI
|
|
41
|
Dobson JM, Samuel S, Milstein H, Rogers K
and Wood JL: Canine neoplasia in the UK: Estimates of incidence
rates from a population of insured dogs. J Small Anim Pract.
43:240–246. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Arnold-Gloor S, Hubler M and Reichler I:
Diseases of the mammary glandPlacement of teh dog clinic. Suter PF,
Arnold-Gloor S and Niemand HG: Parey; Stuttgart: pp. 881–883. 2006,
(In German).
|
|
43
|
Baba AI, Câtoi C and Baba AI: Mammary
gland tumours-comparative oncology. The publishing house of the
Romanian academy; Bucharest: pp. 1online resource. 2007, https://www.ncbi.nlm.nih.gov/books/NBK9557/Accessed
August 31, 2015.
|
|
44
|
Sorenmo K: Canine mammary gland tumors.
Vet Clin North Am Small Anim Pract. 33:573–596. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Novosad CA: Principles of treatment for
mammary gland tumors. Clin Tech Small Anim Pract. 18:107–109. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Queiroga FL, Raposo T, Carvalho MI, Prada
J and Pires I: Canine mammary tumours as a model to study human
breast cancer: Most recent findings. In vivo. 25:455–465.
2011.PubMed/NCBI
|
|
47
|
de Las Mulas JM, Millán Y and Dios R: A
prospective analysis of immunohistochemically determined estrogen
receptor alpha and progesterone receptor expression and host and
tumor factors as predictors of disease-free period in mammary
tumors of the dog. Vet Pathol. 42:200–212. 2005. View Article : Google Scholar
|
|
48
|
Queiroga FL, Pérez-Alenza MD, Silvan G,
Peña L, Lopes C and Illera JC: Role of steroid hormones and
prolactin in canine mammary cancer. J Steroid Biochem Mol Biol.
94:181–187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Torres CG, Pino AM and Sierralta WD: A
cyclized peptide derived from alpha fetoprotein inhibits the
proliferation of ER-positive canine mammary cancer cells. Oncol
Rep. 21:1397–1404. 2009.PubMed/NCBI
|
|
50
|
Wakui S, Muto T, Yokoo K, Yokoo R,
Takahashi H, Masaoka T, Hano H and Furusato M: Prognostic status of
p53 gene mutation in canine mammary carcinoma. Anticancer Res.
21:611–616. 2001.PubMed/NCBI
|
|
51
|
Lee CH and Kweon OK: Mutations of p53
tumor suppressor gene in spontaneous canine mammary tumors. J Vet
Sci. 3:321–325. 2002.PubMed/NCBI
|
|
52
|
Carvalho MI, Pires I, Prada J and Queiroga
FL: A role for T-lymphocytes in human breast cancer and in canine
mammary tumors. Biomed Res Int. 2014:1308942014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Haga S, Nakayama M, Tatsumi K, Maeda M,
Imai S, Umesako S, Yamamoto H, Hilgers J and Sarkar NH:
Overexpression of the p53 gene product in canine mammary tumors.
Oncol Rep. 8:1215–1219. 2001.PubMed/NCBI
|
|
54
|
Tao JJ, Visvanathan K and Wolff AC: Long
term side effects of adjuvant chemotherapy in patients with early
breast cancer. Breast. 24(Suppl 2): S149–S153. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bracha S, Walshaw R, Danton T, Holland S,
Ruaux C and Obradovich J: Evaluation of toxicities from combined
metronomic and maximal-tolerated dose chemotherapy in dogs with
osteosarcoma. J Small Anim Pract. 55:369–374. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Selmic LE, Burton JH, Thamm DH, Withrow SJ
and Lana SE: Comparison of carboplatin and doxorubicin-based
chemotherapy protocols in 470 dogs after amputation for treatment
of appendicular osteosarcoma. J Vet Intern Med. 28:554–563. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Stratmann N, Failing K, Richter A and
Wehrend A: Mammary tumor recurrence in bitches after regional
mastectomy. Vet Surg. 37:82–86. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Betz D, Schoenrock D, Mischke R,
Baumgärtner W and Nolte I: Postoperative treatment outcome in
canine mammary tumors. Multivariate analysis of the prognostic
value of pre- and postoperatively available information. Tierarztl
Prax Ausg K Kleintiere Heimtiere. 40:235–242. 2012.(In English,
German). PubMed/NCBI
|
|
59
|
Hay M, Thomas DW, Craighead JL, Economides
C and Rosenthal J: Clinical development success rates for
investigational drugs. Nat Biotechnol. 32:40–51. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Marchetti S and Schellens JH: The impact
of FDA and EMEA guidelines on drug development in relation to Phase
0 trials. Br J Cancer. 97:577–581. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Stapff M: Drug trials: An introduction to
clinical trials for doctors, students, medical assistants and
interested laymen. 5th. Zuckschwerdt; Munich: 2008
|
|
62
|
Directive 2010/63/EU, . Directive
2010/63/EU of the European Parliament and of the Council of 22
September 2010 on the protection of animals used for scientific
purposes. 2010, simpleeur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:en:PDFAccessed
May 17, 2016.
|
|
63
|
European Medicines Agency. ICH-GCP: ICH
Topic E6 (R1) Guideline for Good Clinical Practice. 2002,
simpleeur-lex.europa.eu/legalcontent/EN/TXT/?uri=celex%3A32010L0063Accessed
August 31, 2015.
|
|
64
|
National Institutes of Health. U.S.
National Library of Medicine: Clinical Trial Phases. 2015,
simpleclinicaltrials.govAccessed August 31,
2015.
|
|
65
|
Ciociola AA, Cohen LB and Kulkarni P:
FDA-Related Matters Committee of the American College of
Gastroenterology: How drugs are developed and approved by the FDA:
Current process and future directions. Am J Gastroenterol.
109:620–623. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Khanna C, London C, Vail D, Mazcko C and
Hirschfeld S: Guiding the optimal translation of new cancer
treatments from canine to human cancer patients. Clin Cancer Res.
15:5671–5677. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Monath TP, Kahn LH and Kaplan B:
Introduction: One health perspective. ILAR J. 51:193–198. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Séveré S, Marchand P, Guiffard I, Morio F,
Venisseau A, Veyrand B, Le Bizec B, Antignac JP and Abadie J:
Pollutants in pet dogs: A model for environmental links to breast
cancer. Springerplus. 4:272015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kelsey JL, Moore AS and Glickman LT:
Epidemiologic studies of risk factors for cancer in pet dogs.
Epidemiol Rev. 20:204–217. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hansen K and Khanna C: Spontaneous and
genetically engineered animal models; use in preclinical cancer
drug development. Eur J Cancer. 40:858–880. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Fürdös I, Fazekas J, Singer J and
Jensen-Jarolim E: Translating clinical trials from human to
veterinary oncology and back. J Transl Med. 13:2652015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Jensen-Jarolim E: Definition of
comparative medicine: History and new identityComparative Medicine.
Anatomy and Physiology. Springer; Wien: pp. 1–18. 2014
|
|
73
|
Singer J and Jensen-Jarolim E: IgE-based
immunotherapy of cancer-a comparative oncology approach. J Carcinog
Mutagen. 5:10001762014. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Merlo DF, Rossi L, Pellegrino C, Ceppi M,
Cardellino U, Capurro C, Ratto A, Sambucco PL, Sestito V, Tanara G
and Bocchini V: Cancer incidence in pet dogs: Findings of the
Animal Tumor Registry of Genoa, Italy. J Vet Intern Med.
22:976–984. 2008. View Article : Google Scholar : PubMed/NCBI
|
